WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012102521) HUMAN ANTI-CD23 FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING SAME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/102521    International Application No.:    PCT/KR2012/000521
Publication Date: 02.08.2012 International Filing Date: 20.01.2012
IPC:
C12N 15/12 (2006.01), C12N 15/70 (2006.01), C12N 1/21 (2006.01), C07K 16/18 (2006.01), A61K 39/395 (2006.01), A61P 35/02 (2006.01)
Applicants: IG THERAPY [KR/KR]; Gangwon National Univ. c/o 192-1, Hyoja-dong Chuncheon-si Gangwon-do 200-701 (KR) (For All Designated States Except US).
CHA, Sang Hoon [KR/KR]; (KR) (For US Only)
Inventors: CHA, Sang Hoon; (KR)
Agent: KIM, Moon Jae; KAL Bldg. 3rd Fl., 41-3 Seosomun-Dong Jung-Gu Seoul 100-813 (KR)
Priority Data:
10-2011-0008403 27.01.2011 KR
Title (EN) HUMAN ANTI-CD23 FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING SAME
(FR) ANTICORPS FAB ANTI-CD23 HUMAIN ET COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE TUMEURS LE COMPRENANT
(KO) 인간 항-CD23 Fab 항체 및 이를 포함하는 종양 치료용 약학 조성물
Abstract: front page image
(EN)The present invention relates to a Fab antibody that binds specifically to CD23 which is expressed on the IM-9 cell surface, and to a pharmaceutical composition for treating tumours comprising the same. In use, the anti-CD23 human Fab antibody according to the present invention is highly specific for CD23 and so can provide a pharmaceutical composition for treating tumours and a pharmaceutical composition for treating leukemia.
(FR)La présente invention concerne un anticorps Fab qui se lie spécifiquement à CD23 qui est exprimé sur la surface d'une cellule IM-9, et une composition pharmaceutique pour le traitement de tumeurs, comprenant celui-ci. En utilisation, l'anticorps Fab humain anti-CD23 selon la présente invention est hautement spécifique pour CD23 et peut ainsi fournir une composition pharmaceutique pour le traitement de tumeurs et une composition pharmaceutique pour le traitement de la leucémie.
(KO)본 발명은 IM-9 세포 표면에 발현하는 CD23에 특이적으로 결합하는 Fab 항체 및 이를 포함하는 종양 치료용 약학조성물에 관한 것으로, 본 발명에 따른 항-CD23 인간 Fab 항체를 이용하면, CD23에 대한 특이성이 높아서, 종양 치료용 약학 조성물 및 백혈병 치료용 약학조성물을 제공할 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)